Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07491380 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TDHOME)

Study acronym: TDHOME
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 39 days later Dec 15, 2027 → Jan 23, 2028
See other at-risk trials from Institut Curie

Record History

  1. Recruitment openedv3 Show 4 more changesShow less
    • Start date: May 15, 2026 to Jun 23, 2026
    • Primary completion pushed from Dec 15, 2027 to Jan 23, 2028
    • Study completion pushed from Dec 15, 2028 to Jan 23, 2029
    • Site details revised at 2 of 2 sites
  2. Study sites: 1 to 2v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institut Curie
43 trials monitored
See 1 trial at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
This is a prospective validation study, multicenter, open-label, single-arm study, evaluating the concordance between capillary microsampling (using the VAMS Mitra device) and venous sampling in patients undergoing CDK4/6 therapy.
Trial Details
NCT Number NCT07491380
Lead Sponsor Institut Curie
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov